ROLE OF ROSUVASTATIN PRETREATMENT IN PREVENTION OF CONTRAST INDUCED NEPHROPATHY IN PATIENTS UNDERGOING CORONARY ANGIOGRAPHY

Abstract

Objective: The aim of this study was to assess the efficacy of short-term highdose rosuvastatin pretreatment therapy for the prevention of contrast induced nephropathy. Methodology: This study prospectively included two hundred patients who underwent coronary angiography, and were randomized into two groups: control group (included 100 patients who did not receive statin therapy) and statin group (included 100 patients who received rosuvastatin 20 mg/day 3 days before and 7 days after coronary angiography).According to recommendations of the National kidney foundation, results had been recorded using both serum creatinine and glomular filteration rate levels. Results: There was statistically significant reduction in the occurrence of contrast-induced nephropathy in rosuvastatin pretreated patients ("22%" and "15%" of them developed contrast-induced nephropathy regarding the glomular filteration rate and serum creatinine levels respectively), compared to those in the control group ("35%" and "38%" regarding the glomular filteration rate and serum creatinine levels respectively) with P-value (<0.001 regarding serum creatinine and <0.042 regarding glomular filteration rate). Conclusion: This study favors statin pretreatment for preventing contrast induced nephropathy in patients undergoing coronary angiography.